By Huang Jianwen King & Wood Mallesons’Commercial & Regulatory Group
On July 25, 2016, the China Food and Drug Administration (“CFDA”) published the Administrative Provisions for Drug Registration (Revision) (the “Draft for Comment”) and submitted the Draft for Comment for public opinions. Composing of 8 chapters and 147 provisions in total,